EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Feasibility and efficacy of fecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: A randomized clinical pilot trial

Clara M A de Bruijn, Anna O J Oorthuys iD, Judith Zeevenhooven, Mark Davids, Johannes H M Levels, Arine M Vlieger, Hilde Herrema, Max Nieuwdorp, Marc A Benninga

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70459 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Clara M A de Bruijn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Pediatric Gastroenterology, Hepatology and Nutrition, Amster…. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Irritable Bowel Syndrome. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Dioraphte, For Wis(h)dom Foundation, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the feasibility and efficacy of fecal microbiota transplantation (FMT) in adolescents (16–21 years) with refractory irritable bowel syndrome (IBS).

Methods

Randomized controlled pilot trial. Thirty‐two patients were included and randomized to receive two allogeneic or autologous FMTs. At baseline and after 6 weeks, two allogeneic or autologous FMTs were administered via a nasoduodenal tube. Feasibility outcomes included dropout rate. Clinical efficacy was evaluated by the proportion of responders (≥50 points reduction in total score of the IBS severity‐scoring‐system) at 12, 24, and 48 weeks follow‐up. Secondary outcomes included health‐related quality of life (QoL), depression and anxiety scores, and school/work absenteeism.

Results

One patient (3%) withdrew after randomization, due to lack of effect after the first FMT. Response rates 12 weeks after allogeneic and autologous FMTs were 40% and 38% ( p = 0.886). At 24 weeks, significantly more patients responded after allogeneic FMTs (60% vs. 25% autologous, p = 0.048), without significant differences at 48 weeks (60% vs. 50%, p = 0.576). Total QoL score was significantly better after allogeneic than autologous FMTs at 12, 24, and 48 weeks ( p = 0.028, p = 0.007, p = 0.011). In the allogeneic FMTs group, school/work absenteeism was 7% at 24 weeks (vs. 41% autologous, p = 0.037).

Conclusions

Allogeneic FMTs were feasible and resulted in high response rates and better QoL compared to autologous FMTs. These results provide preliminary evidence for the use of allogeneic FMTs in adolescents with refractory IBS. Trial Registration ClinicalTrials.gov identifier: NCT03074227 ( https://clinicaltrials.gov/study/NCT03074227?id=NCT03074227&rank=1 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationIrritable Bowel SyndromeHumansAdolescentPilot ProjectsFemaleMaleFeasibility StudiesQuality of LifeTreatment OutcomeYoung AdultTransplantation, AutologousTransplantation, HomologousAbsenteeism

Stichwörter der Autor:innen

abdominal paingut microbiomemicrobiota‐based therapypediatric gastroenterology

Autor:innen und Institutionen

  • Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Pediatric Gastroenterology, Hepatology and Nutrition, Amsterdam, the Netherlands.
  • Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, Location Academic Medical Center/Emma Children's Hospital, Amsterdam, the Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Gastroenterology and Hepatology, Amsterdam, the Netherlands.
  • Departments of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, the Netherlands.
  • Department of Pediatrics, St. Antonius Hospital, Nieuwegein, the Netherlands.

ORCID-Profile: Anna O J Oorthuys

Förderung

  • Stichting Dioraphte
  • For Wis(h)dom Foundation
  • ZonMw
  • Aspasia Premium

Zitieren

APA

de Bruijn, C. M. A., Oorthuys, A. O. J., Zeevenhooven, J., Davids, M., Levels, J. H. M., Vlieger, A. M., Herrema, H., Nieuwdorp, M., & Benninga, M. A. (2026). Feasibility and efficacy of fecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: A randomized clinical pilot trial. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70459

Vancouver

de Bruijn CMA, Oorthuys AOJ, Zeevenhooven J, Davids M, Levels JHM, Vlieger AM, et al. Feasibility and efficacy of fecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: A randomized clinical pilot trial. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70459

BibTeX
@article{deBruijn2026,
  author = {de Bruijn, Clara M A and Oorthuys, Anna O J and Zeevenhooven, Judith and Davids, Mark and Levels, Johannes H M and Vlieger, Arine M and Herrema, Hilde and Nieuwdorp, Max and Benninga, Marc A},
  title = {Feasibility and efficacy of fecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: A randomized clinical pilot trial},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70459}
}
Kostenlos starten →